B. Riley has launched coverage of Microbot Medical (NASDAQ:MBOT) with a Buy rating and a $5.00 price target, representing an implied upside of approximately 172% from the stock's current trading level of $1.84. InvestingPro consensus remains constructive on the name, with the high analyst target listed at $12.00.
The timing of B. Riley's initiation comes after two regulatory and commercial milestones for Microbot Medical. The company received FDA 510(k) clearance for its LIBERTY Endovascular Robotic System in September 2025 and began a limited U.S. market release in November 2025. The $123.57 million market capitalization company is slated to report next quarter results on February 25, 2026.
Emory University Hospital in Atlanta is reported as the first hospital to put the LIBERTY system into clinical use. The platform is described as the first and only single-use, remotely operated robotic device cleared by the FDA for peripheral vascular procedures. According to B. Riley, the system targets a substantial addressable market in peripheral vascular care - more than 2.3 million procedures are performed annually in the U.S. and, per the firm's note, there is currently no robotic competition in that niche.
B. Riley emphasized the commercial distinction of LIBERTY's single-use model. Unlike traditional capital-intensive robotics that require large upfront expenditures and are treated as capital equipment, LIBERTY is fully disposable and billed through operating budgets for hospitals and ambulatory surgery centers. The analyst suggests that this consumption-style cost structure could facilitate a faster commercial adoption curve compared with capital-equipment competitors.
On the balance sheet front, InvestingPro data cited by the initiating firm indicates Microbot Medical carries more cash than debt and reports a strong current ratio of 27.53. Those liquidity metrics are presented as supportive for the company's early commercialization efforts.
Microbot's recently reported third-quarter 2025 financials show a net loss of $3.6 million, or $0.07 per share, slightly wider than the analyst estimate of a $3.4 million loss. The quarter ended September 2025 with $80.2 million in cash and investments, while operating activities produced negative cash flow of $3.8 million for the period.
Investor attention to Microbot has increased as the LIBERTY system sees initial clinical deployment. Following the first hospital adoption, other analysts have also acted: Roth/MKM initiated coverage with a Buy rating and a $5.50 price target, and H.C. Wainwright reiterated its Buy stance and maintained a $12.00 target. These moves indicate a cluster of positive analyst sentiment centered on early commercial traction and the LIBERTY platform's positioning.
For shareholders and market observers, key near-term events include the company's upcoming earnings release on February 25, 2026, and the broader commercialization progress of LIBERTY in U.S. hospitals and surgery centers. The company’s liquidity profile and the disposable nature of its robotic offering are highlighted as supporting factors for initial market roll-out, while reported quarterly losses and negative operating cash flow remain elements market participants will monitor.